Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects

Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Patients Under the "New-Drug Re-examination

The objective of this study is to evaluate the safety profile of Adalimumab for Hidradenitis Suppurativa (HS) participants in normal medical practice.

Inclusion Criteria:

• Participant who are eligible to be treated with adalimumab for HS in accordance with the approved Korean label
• Participant must provide written authorization form to use their personal health data prior to the participating in the study.

Exclusion Criteria:

• Participant who are contraindications to adalimumab as listed on the approved Korean label.
• Participant who is participating on other clinical trials.